Pharmacist Madeline Acquilano inoculates a teacher with the Johnson & Johnson Covid-19 Vaccine at Hartford Hospital in Hartford, Connecticut, on March 3, 2021.
Joseph Prezioso | AFP | Getty Images
A Centers for Disease Control and Prevention panel on Wednesday decided to postpone a decision on Johnson & Johnson’s Covid-19 vaccine while it investigates cases of six women developing a rare but potentially life-threatening blood-clotting disorder that left one dead and one in critical condition.
The CDC’s Advisory Committee on Immunization Practices met a day after the Food and Drug Administration asked states to temporarily halt using J&J’s vaccine “out of an abundance of caution.” The panel voted unanimously to reconvene in a week, when it will decide what it will recommend to the CDC on J&J’s vaccine.
The postponement means the pause on J&J’s vaccine will remain in effect.
The committee debated whether to and how long they wanted to continue the pause on J&J’s vaccine while the CDC investigates the cause of the blood clotting. One committee member recommended a monthlong hold on restarting immunizations, while other members recommended a few weeks. Some members asked whether they could hold off on voting until they had more time to digest the data.
One of the options the panel considered was whether to recommend limiting the vaccine’s use based on age or other risk factors.
Dr. Grace Lee, a member of the committee, said she worried a vote to pause the use of the vaccine indefinitely would send the wrong message to the public. She and others added it could make it appear that something is fundamentally wrong with the vaccine.
“That is not the decision I think makes the most sense,” she said.
Sandra Fryhofer of the American Medical Association was in favor of a pause. She said there is enough supply of the Moderna and Pfizer vaccines to continue rapid vaccinations across the U.S.
“I know there are many patients that have not been able to get vaccinated that need to get vaccinated, but we want to make sure these vaccines are safe,” she said.
Dr. Nirav Shah, the director for the CDC in Maine, said the committee’s vote to postpone a decision on the use of the vaccine is “tantamount to making a decision.”
“Any extension of the pause will invariably result in the fact that the most vulnerable individuals in the United States who were prime candidates for the J&J vaccine will remain vulnerable. The most at risk will remain at risk.”
The CDC and FDA advised states to reschedule J&J vaccine appointments after six women developed cerebral venous sinus thrombosis, or CVST, within about two weeks of receiving the shot, U.S. health officials told reporters on Tuesday. CVST is a rare form of a stroke that happens when a blood clot forms in the brain’s venous sinuses. It can eventually leak blood into the brain tissues and cause a hemorrhage.
“CVST is rare but clinically serious and can result in substantial morbidity and mortality,” Dr. Tom Shimabukuro, a CDC official, told the committee. He said the CVST cases appeared to be three times greater in the J&J vaccine group than among women ages 20 to 50 years old with similar backgrounds.
Within hours of the FDA’s warning early Tuesday, more than a dozen states as well as some national pharmacies halted inoculations with J&J’s vaccine, some replacing scheduled appointments with either the Pfizer or Moderna vaccine.
U.S. health officials had said the pause on the use of the vaccine might last only a matter of days, depending on what they learn in their investigation of the cases. White House chief medical advisor Dr. Anthony Fauci said Tuesday the pause on the use of the vaccine would give U.S. health regulators the time they need to thoroughly investigate the cases and “find some common denominators among the women who were involved.”
A 25-year-old man developed CVST along with a hemorrhage during the clinical trial; he was hospitalized but recovered. All of the six cases that occurred after the clinical trial were found in white women, Shimabukuro said, noting that the median time to symptom onset was eight days. Three were described as obese, one had hyperthyroidism, one had asthma and one had hypertension, he said.
Five of the six patients initially developed headaches and one had back pain and bruising before more serious other symptoms set in, he said. One of the women has died. Three of the patients remain hospitalized, while two have been discharged, he said.
“These are significant blood clots that are causing these problems,” he said.
Dr. Aaran Maree, chief medical officer for J&J’s vaccine division, Janssen Pharmaceutical Cos., told the committee that none of the women were on birth control, which was theorized as a possible link to the blood clotting. They also all tested negative for Covid-19.
One of the two patients who recovered was a 26-year-old woman who was described as “overweight but active,” wasn’t on any medication and had no history of clotting disorder.
She was admitted to the hospital with a severe headache a week after receiving the J&J vaccine and was discharged but returned to the hospital a week later with abdominal pain and a rapid heart rate, he said. Tests revealed she developed thrombocytopenia, or a low level of platelets in the blood, and CVST.
One 48-year-old woman with an “unremarkable past medical history” was admitted to the hospital after three days of malaise and abdominal pain. She developed severe thrombocytopenia and CVST that progressed with hemorrhagic stroke despite treatment with the blood thinner heparin. She received the J&J vaccine two weeks prior to symptom onset and remains critically ill, according to the last report.